ALT5 Sigma (NASDAQ:ALTS) versus Imation (OTCMKTS:GLAE) Financial Review

ALT5 Sigma (NASDAQ:ALTS) and Imation (OTCMKTS:GLAE) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Insider and Institutional Ownership

6.3% of ALT5 Sigma shares are owned by institutional investors. 0.7% of ALT5 Sigma shares are owned by insiders. Comparatively, 9.2% of Imation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for ALT5 Sigma and Imation, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
Imation	0	0	0	0	0.00

Profitability

This table compares ALT5 Sigma and Imation’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	133.06%	8.60%	7.10%
Imation	N/A	N/A	N/A

Earnings and Valuation

This table compares ALT5 Sigma and Imation”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$12.53 million	19.84	-$6.24 million	N/A	N/A
Imation	N/A	N/A	N/A	N/A	N/A

Imation has lower revenue, but higher earnings than ALT5 Sigma.

Risk and Volatility

ALT5 Sigma has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Imation has a beta of 7.44, suggesting that its share price is 644% more volatile than the S&P 500.

Summary

ALT5 Sigma beats Imation on 6 of the 8 factors compared between the two stocks.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

About Imation

GlassBridge Enterprises, Inc., through its subsidiaries, owns and operates an asset management business in the United States. It offers investment advisory services to third party investors through managed funds separate managed accounts. The company was formerly known as Imation Corp. and changed its name to GlassBridge Enterprises, Inc. in February 2017. GlassBridge Enterprises, Inc. was incorporated in 1996 and is headquartered in New York, New York.